Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

References

• World Health Organization [webpage on the Internet]Antimicrobial Resistance: Global Report on Surveillance, 20142014 Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1Accessed March 20, 2016
   Google Scholar
• CosgroveSEThe relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costsClin Infect Dis200642suppl 2S82S8916355321
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention [webpage on the Internet]Antibiotic Resistance Threats in the United States, 20132013 Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdfAccessed February 3, 2016
   Google Scholar
• ChenJShangXHuFBeta-lactamase inhibitors: an updateMini Rev Med Chem201313131846186123895190
   PubMed Web of Science ®Google Scholar
• SharmaRParkTEMoySCeftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination for the treatment of resistant gram-negative organismsClin Ther201638343144426948862
   PubMed Web of Science ®Google Scholar
• Avycaz (Ceftazidime-Avibactam) [package insert]Cincinnati, OHForest Pharmaceuticals2015
   Google Scholar
• CastanheiraMFarrellSEWangerARolstonKVJonesRNMendesRERapid expansion of KPC-2-producing Klebsiella pneumoniae isolates in two Texas hospitals due to clonal spread of ST258 and ST307 lineagesMicrob Drug Resist201319429529723530541
   PubMed Web of Science ®Google Scholar
• TzouvelekisLSMarkogiannakisAPsichogiouMTassiosPTDaikosGLCarbapenemases in Klebsiella pneumoniae and other enterobacteriaceae: an evolving crisis of global dimensionsClin Microbiol Rev201225468270723034326
   PubMed Web of Science ®Google Scholar
• WoodfordNTurtonJFLivermoreDMMultiresistant gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistanceFEMS Microbiol Rev201135573675521303394
   PubMed Web of Science ®Google Scholar
• AktaşZKayacanCOnculOIn vitro activity of avibactam (NXL104) in combination with β-lactams against gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniaeInt J Antimicrob Agents2012391868922041508
   PubMed Web of Science ®Google Scholar
• HumphriesRMYangSHemarajataPFirst report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolateAntimicrob Agents Chemother201559106605660726195508
   PubMed Web of Science ®Google Scholar
• AstraZeneca; PRA Health Sciences [webpage on the Internet]Evaluation of Safety, Pharmacokinetics and Efficacy of CAZ-AVI with Metronidazole in Children Aged 3 Months to 18 Years Old with Complicated Intra-abdominal Infections (cIAIs)ClinicalTrials gov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited March 24, 2016]. Available from: http://clinicaltrials.gov/show/NCT02475733
   Google Scholar
• LucastiCPopescuIRameshMLipkaJSableCComparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trialJ Antimicrob Chemother20136851183119223391714
   PubMed Web of Science ®Google Scholar
• VazquezJGonzález PatzánLStricklinDEfficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized studyCurr Med Res Opin201228121921193123145859
   PubMed Web of Science ®Google Scholar
• MazuskiJEGasnikLAmstrongJEfficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection-results from a Phase III program (Abstract O191)25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)Copenhagen2015
   Google Scholar
• LevasseurPGirardAMClaudonMIn vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolatesAntimicrob Agents Chemother20125631606160822214778
   PubMed Web of Science ®Google Scholar
• ColemanKDiazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitorsCurr Opin Microbiol201114555055521840248
   PubMed Web of Science ®Google Scholar
• SaderHCastanheiraMFlammRFarrellDJJonesRNAntimicrobial activity of ceftazidime-avibactam against gram-negative organisms collected from U.S. medical centers in 2012Antimicrob Agents Chemother20135831684169224379201
   PubMed Web of Science ®Google Scholar
• AndrewsJMDetermination of minimum inhibitory concentrationsJ Antimicrob Chemother200148suppl 151611420333
   PubMed Web of Science ®Google Scholar
• KeepersTRGomezMCeleriCNicholsWWKrauseKMBactericidal activity, absence of serum effect, and time-kill kinetics of ceftazidime-avibactam against β-lactamase-producing enterobacteriaceae and Pseudomonas aeruginosaAntimicrob Agents Chemother20145895297530524957838
   PubMed Web of Science ®Google Scholar
• LahiriSDWalkupGKWhiteakerJDSelection and molecular characterization of ceftazidime/avibactam-resistant mutants in Pseudomonas aeruginosa strains containing derepressed AmpCJ Antimicrob Chemother20157061650165825645206
   PubMed Web of Science ®Google Scholar
• MerdjanHRangarajuMTarralASafety and pharmacokinetics of single and multiple ascending doses of avibactam alone and in combination with ceftazidime in healthy male volunteers: results of two randomized, placebo-controlled studiesClin Drug Investig2015355307317
   PubMed Web of Science ®Google Scholar
• BealeJAntibacterial antibioticsBealeJBlockJWilson and Gisvold’s Textbook of Organic Medicinal and Pharmaceutical Chemistry12th edBaltimoreLippincott Williams & Wilkins2011258329
   Google Scholar
• CaprileKThe cephalosporin antimicrobial agents: a comprehensive reviewJ Vet Pharmacol Ther19881111323288766
   PubMed Web of Science ®Google Scholar
• DunnGCeftizoxime and other third-generation cephalosporins: structure-activity relationshipsJ Antimicrob Chemother198210suppl C1106295993
   PubMedGoogle Scholar
• NeuHβ-Lactamase stability of cefoxitin in comparison with other β-lactam compoundsDiagn Microbiol Infect Dis1983143133166321094
   PubMed Web of Science ®Google Scholar
• NeuHβ-lactam antibiotics: structural relationships affecting in vitro activity and pharmacologic propertiesClin Infect Dis19868suppl 3S237S259
   Google Scholar
• AstraZeneca [webpage on the Internet]A Study Comparing Ceftazidime-Avibactam versus Meropenem in Hospitalized Adults with Nosocomial PneumoniaClinicalTrialsgov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited March 24, 2016]. Available from: http://clinicaltrials.gov/show/NCT01808092Accessed June 10, 2016
   Google Scholar
• University of Southern California [webpage on the Internet]Steady-State Pharmacokinetics of Ceftazidime/Avibactam in Cystic FibrosisClinicalTrials.gov [Internet]Bethesda, MDNational Library of Medicine (US)2000 [cited March 24, 2016]. Available from: http://clinicaltrials.gov/show/NCT02504827Accessed June 10, 2016
   Google Scholar
• VollmerWBlanotDDe PedroMPeptidoglycan structure and architectureFEMS Microbiol Rev200832214916718194336
   PubMed Web of Science ®Google Scholar
• SauvageEKerffFTerrakMAyalaJACharlierPThe penicillin-binding proteins: structure and role in peptidoglycan biosynthesisFEMS Microbiol Rev200832223425818266856
   PubMed Web of Science ®Google Scholar
• MawalYCritchleyIARiccobeneTATalleyAKCeftazidime–avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infectionsExpert Rev Clin Pharmacol20158669170726420166
   PubMed Web of Science ®Google Scholar
• DallowJOttersonLGHubandMDKrauseKMNicholsWWMicrobiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classesInt J Antimicrob Agents201444655255625293578
   PubMed Web of Science ®Google Scholar
• VishwanathanKMairSGuptaAAssessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potentialDrug Metab Dispos201442593294224616266
   PubMed Web of Science ®Google Scholar
• Fortaz [package insert]Schaumburg, IllinoisSagent Pharmaceuticals Inc2014
   Google Scholar